Nootropics are substances converted from pyroglutamate, which is commonly found in fruits and vegetables. Nootropic drugs are able to increase the number of acetylcholine receptors in the brain, thereby improving brain utilization.

With the increasing trend of urbanization and aging, the elderly population in China has exceeded 120 million, and the incidence of geriatric diseases, especially mental diseases, is also increasing year by year. With the increase of residents' income, the requirements for the quality of life of the elderly also increase. Under this trend, for the treatment of mental diseases such as senile dementia drug demand is increasing sharply. In drug category, WHO will work on the spirit of medicine and educational to the merger, we through the acquisition of Chinese medicine institute of more than 300 domestic major hospital clinical medication data to make a brief analysis of the development trend of drugs.

This class of drugs in the overall market size is about 1.22 billion yuan, the sales amount of 2002 rose by only 5.0%, but sales rose by 11.2%, sales amount a failure with the sales quantity is the main reason for the rise is the main varieties in this kind of drugs, such as pyrazole raschig, cobalt amide and ginkgo leaf, In 2002, the price of sales units fell sharply due to bidding. Ginkgo biloba preparations occupy the largest market share in this category, with a market share of more than 1/3, ganglioside and cobin also occupy nearly 1/3 of the market share, piracetam and other "cetan" drugs occupy nearly 10% of the market share, and the rest of the drugs have their own share of less than 5%. At present, there are more than 20 production enterprises of ginkgo biloba and more than 70 production enterprises of piracetam, all of which have entered the stage of price competition and their profits have been diluted again and again.

Among the first-line varieties, except for Ginkgo biloba preparation, the growth of other varieties was weak, especially the traditional variety piracetam suffered a "heavy hit" by bidding and procurement, and there was no recovery, and the sales of aniracetam also declined. The sharp decline of "acetam" drugs was the main factor causing the decline of the market growth rate of this kind of drugs. But observe the second line of new varieties of rice and A few can be found that this class of drugs in new varieties of great potential and A few second line varieties such as alkali Shi Sha A, donnelly, pp's rise are showing A big jump, rapid development momentum. As more new dementia drugs are gradually entering the market, the market potential is further expanded, and the market will face increasing competitive pressure.